This paper, written by an expert panel on behalf of the International Myeloma Working Group, addresses the need for new uniform response criteria for myeloma patients.
IMWG Consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation
This article, produced by the International Myeloma Working Group, reviews the current literature and provides important perspectives and guidance on the major issues surrounding the optimal current management of transplantation-eligible myeloma patients.
IMWG Guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation
This paper provides an update to the first guideline published in 2005 by the International Myeloma Working Group on the management of myeloma patients who are ineligible for high-dose therapy and autologous stem cell transplantation. It includes recommendations on the diagnosis and treatment of these patients together with the management of side-effects of treatment.
This paper, written by an interdisciplinary panel of experts in myeloma and myeloma bone disease, reviews the available evidence and provides recommendations for the management of myeloma-related bone disease. It also includes expert consensus to propose additional recommendations where there were insufficient published data.
This paper provides updated guidelines on the diagnosis and management of solitary plasmacytoma of bone, extramedullary plasmacytoma and multiple solitary plasmacytomas and incorporates further available information on diagnosis, prognosis and management and a new section on the management of multiple solitary plasmacytomas.
Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance
These guidelines, written by the UK Myeloma Forum in conjunction with the Nordic Myeloma Study Group provide guidance for the effective clinical investigation of patients with newly detected paraprotein and the practical management of patients with monoclonal gammopathy of undetermined significance (MGUS).
Maintaining results of successful induction treatment is an important goal in myeloma and the use of maintenance treatment to achieve this has been investigated for a number of years. Here, members of the International Myeloma Working Group review the relevant data and draw a consensus on maintenance treatment in myeloma.
IMWG Consensus perspectives: risk factors for progression and guidelines for monitoring and management of MGUS and smouldering myeloma
In this article, members of the International Myeloma Working Group review the available data and provide new recommendations for the management of MGUS and smouldering myeloma patients.
In this paper, members of the International Myeloma Working Group summarise the data from prospective and retrospective studies of allogeneic stem cell transplantation in myeloma and provide recommendations for new safer approaches whilst preserving the graft versus myeloma effect.
IMWG Recommendations for the prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
This paper, produced by the International Myeloma Working Group, summarises the available evidence and provides recommendations for a prophylaxis strategy according to a risk assessment model, to reduce the risk of a venous thromboembolic event in myeloma patients.